All patients in France are typed for ABO blood group, and for the main antigens of the RH (D, C, E, c, e) and KEL (K) systems. SCD patients are also typed for the main antigens of the FY (Fy a , Fy b ), JK (Jk a , Jk b ), and MNS (M, N, S, s) systems. Typing for these antigens is part of the initial workup for SCD patients and is generally performed before the first transfusion.
Introduction
Sickle cell disease (SCD) is a major concern in transfusion medicine in France. It is one of the most frequent genetic disorders, affecting approximately 14,000 patients nationwide, mostly of African descent. Patient care is often based on packed red blood cell (pRBC) transfusions to sustain patients and limit complications.
Blood Group Genotyping
Blood group genotyping has been used for more than 15 years in France and is becoming increasingly important in transfusion medicine. Specialists make particular use of this technique in the following common situations: i) positive results in a direct antiglobulin test (DAT), ii) recent transfusion episodes precluding blood group phenotyping, iii) typing for blood group systems or antigens for which there are no commercially available reagents, and iv) the detection of molecular variants, especially for the RH blood group system. Due to a lack of commercially available reagents, most molecular variants can be detected only by molecular typing.
French transfusion specialists sometimes request FY, JK, or MNS genotyping for SCD patients, if prior typing data are not available. This may be the case for patients arriving in France after transfusion in other countries or for first-time patients who have never been typed despite French guidelines. When patients are typed S-s-, U-or U var phenotype is deduced from genotype analysis [2] . There are no commercially available reagents for U var phenotype detection.
The prevalence of partial RH antigens and variant RH alleles in SCD patients has recently been investigated in France [11, 17] and elsewhere [15, 18, 19] . SCD patients with variant alleles have been shown to have a higher risk of alloimmunization, in both these and other studies [20] .
These studies have shown that partial RH antigens have a high prevalence and are clinically relevant in SCD populations. In the French studies [11, 17] , 20.8-27.7% of RH:2 (C-positive) SCD patients were found to carry partial RH2 antigens without conventional RH2 antigens, and 8.4% of RH:1 (D-positive) patients were found to carry partial RH1 antigens. These partial antigens are associated with high rates of alloimmunization in SCD patients: anti-RH2 antibodies are detected in 14.3-30% of all patients with partial RH2 antigens [11, 17] , and anti-RH1 antibodies are detected in 17.6% of patients with partial RH1 antigens [11] .
The French Strategy for the Detection of RH Variants
Following the French studies cited above, two important decisions were taken concerning the care of SCD patients in France. Based on the prevalence of variant RH alleles and the clinical consequences of alloimmunization, systematic RH molecular typing was considered to be warranted for SCD patients, except those known to be low responders (no antibody formation despite multiple transfusions), to limit costly genotyping analyses. All considerations and recommendations below relate to high-responder SCD patients (alloimmunized) or SCD patients of unknown responder status (patients who have received few pRBC transfusions or newly diagnosed patients).
Firstly [21] (samples from 2010 and 2011 were tested retrospectively).
Secondly, systematic RH molecular typing for SCD patients has gradually been introduced, nationwide, since December 2014. Three molecular immunohematology laboratories (LIHM) perform RH molecular typing in France ( fig. 1 ). The CNRGS laboratory deals with complex cases of immunization. The Créteil LIHM in the Parisian area (Ile-de-France) received 54% of all samples requiring blood group genotyping in 2017, regardless of indication, and 65% of the SCD samples tested in France, because the Parisian area has the highest SCD patient density in France.
We describe here the results for the Créteil LIHM. In this study, 57% of the SCD samples received originated from the Parisian area (mostly from the Mondor, Necker and Avicenne hospitals), and 39% originated from Guadeloupe (in the French Caribbean) and French Guiana (in South America). The regions of mainland France covered by the Créteil LIHM are the North, East, and Central areas of France (most prescriptions for testing come from Lille and Dijon). For data analysis, these regions were considered together under the heading 'Other regions'. 
(2-3)-CE-D(5)-CE).
†, ‡ Detected by real-time polymerase chain reaction (PCR) assays, as previously described [17] .
§ Initially detected by Sanger sequencing analysis, and subsequently with a specific real-time PCR assay. Variant RH2 antigen detection by serological methods seems to be more common for RN than for Cce S : ambiguous RH2 antigen expression was observed for half the RN samples, but fewer than 1 in 8 of the Cce S samples. This finding is of particular importance, because partial RH2 Cce S seems to be associated with the highest risk of anti-RH2 immunization in SCD patients, as reported in previous studies [17] and in this cohort. One of the 8 patients with anti-RH2 antibodies had RN, and 5 had Cce S . The DIVa(C)-haplotype was found to be extremely rare in SCD patients in France, as it was detected in only 3 patients (0.5% of RH:2 patients). Weak RH2 antigen expression was due to the R Z (RHD*01 associated with RHCE*04) haplotype in some cases. In such cases, the antigen is normal, but there are fewer RH2 antigens per RBC [1] .
2014-2017: Gradual Implementation of Full RH Analysis for SCD Patients
In late 2014, after the study by Silvy and coworkers [11] , the detection of partial RH1, RH3, RH4, and RH5 antigens was gradually introduced for SCD patients in France. Progressive testing was initiated at the Créteil LIHM, beginning with SCD patients in Guadeloupe, French Guiana, and several of the main hospitals in the Parisian area. Over the last 3 years, 1,148 SCD patients have been typed for most of the clinically relevant RH alleles ( fig. 3 ). This typing is based on the RHD and RHCE BeadChip DNA array (BioArray/Immucor ® , Warren NJ, USA), together with several additional assays performed in our laboratory to detect alleles of interest. The c.1136C>T substitution in the DAU0 allele (RHD*10.00) is predicted to be neutral [22] and was not routinely detected at our laboratory. Transfusion specialists agree on the partial status of the RH antigens produced by most of the altered RHD and RHCE alleles common in individuals of African descent (see table 1 20 .02) alleles are not considered to produce partial antigens either. In our experience, the anti-RH5 antibodies associated with these molecular backgrounds are auto-antibodies, and patients are therefore no more prone to the formation of anti-RH4 or anti-RH5 antibodies when exposed to non-genotype-matched pRBCs. The status of the RH1 antigen associated with weak D type 4.0 (RHD*09.03) is also under scrutiny [41] [42] [43] .
Of the 1,148 SCD patients tested for altered alleles of both RHD and RHCE (table 2), at least one partial RH antigen was deduced from genotyping results for 253 (22.0%). The prevalence of partial antigens was similar for SCD patients from the Parisian area and for those from other regions of mainland France. The slightly higher numbers obtained simply reflect the larger numbers of samples sent to our laboratory for testing due to serological discrepancies or antibodies against RH antigens in antigen-positive patients.
Rare RH phenotypes due to homozygously altered alleles were deduced by molecular analysis for 8 patients (0.7%): 1 RH:-31,-34, 1 RH:-18 (homozygous for the ceAR allele RHCE*01.04.01), 3 homozygous for the ceAG allele (RHCE*01.06.01), and 3 homozygous for the ceTI allele (RHCE*01.02.01). In addition, 19 patients (1.7%) were heterozygous for two altered RHCE alleles, a situation associated with an unknown risk of alloimmunization. RH10 (V) and/or RH20 (VS) expression could be deduced for 517 of the 1,148 patients (45.0%).
The prevalence of haplotypes leading to partial RH2 antigen expression varies in the French regions covered by the Créteil LIHM (table 3) . The difference in RN and Cce S haplotype prevalence for all RH:2 SCD patients genotyped from 2010 to 2017 is particularly striking. These differences undoubtedly stem from the specific fea- a Haplotypes and alleles of interest detected in SCD patients of Afro-Caribbean descent in France that have been demonstrated to express one or more partial RH antigens. The table contains references for partial antigen status and RH10 and RH20 antigen expression (see also Daniels et al. [40] ). For clarity, the main haplotypes producing partial RH2 antigens are grouped at the beginning of this table.
*Except for RHCE*CE-DIVa.2(2-3)-CE-D(5)-CE
(the name used in the initial report) for which no ISBT reference is available. † The status of RH1 antigen associated with weak D type 4.0 is controversial [43] . ‡ ceCF also produces some RH1 epitopes. tures of each geographic region, with differences in gene flow and genetic drift. The Parisian area (Ile-de-France) has higher levels of gene flow due to immigration. French Guiana, which is located in South America, has a different mixture. Guadeloupe is an island in the French Caribbean and is, thus, more susceptible to genetic drift.
Overview of Genotyping for the FY, JK, and MNS Blood Group Systems from 2015 to 2017
As stated above, extended genotyping is rarely necessary for SCD patients in France because extended phenotyping is included in the initial workup. Only a small proportion of the total number of SCD samples tested in our laboratory underwent FY, JK and MNS genotyping (fig. 4) . A shift from phenotyping to genotyping would not be cost-effective in France.
Concluding Remarks
This review of current French genotyping practices for SCD patients confirms the results of the previous studies [11, 17] on a larger scale, and reveals differences between the SCD patients of different French regions. Overall, for almost 1 in 4 SCD patients in France at least one partial RH antigen can be deduced from molecular typing. Most of these cases are not picked up by phenotyping and require genotyping for detection.
Several studies have reported allele prevalences for other populations [18, 19, [44] [45] [46] . Partial RH2 antigens appear to be particularly prevalent in mainland France, whereas partial RH1 antigens are more prevalent in Guadeloupe and French Guiana. Conversely, the pattern of variation in RH alleles does not seem to differ across the US [47] . The specific features of French regions overseas may account for this difference. The RHD and RHCE genotyping strategy is being implemented gradually, and is not yet being applied by all French transfusion specialists. Thus, samples with ambiguous antigen expression for one or more RH antigens are still more likely to be sent to our laboratory for further testing. This may affect the allele and haplotype prevalences reported here. The results summarized in this review promote generalized systematic RHD and RHCE genotyping for SCD patients, by showing it would be beneficial for SCD patients.
The large number of partial RH antigens in SCD patients of African descent highlights the importance of detecting these antigens before the occurrence of alloimmunization. The strategy presented here would be improved by advances in our knowledge of the risk of alloimmunization associated with RH variants, particularly for patients heterozygous for two altered RHCE alleles. Furthermore, these analyses would be unnecessary for many patients if it became possible to determine the high-or low-responder status of the individual before the occurrence of alloimmunization. Unfortunately, this is not yet possible, and RH genotyping remains essential for high-responder and newly diagnosed SCD patients.
